NUVATION BIO NUVB 深 沪
已收盘 08-01 16:00:00 美东时间
2.23
-0.130
-5.51%
华盛通- 最 高2.32
- 今 开2.28
- 成交量 360.21万股
- 最 低 2.22
- 昨 收 2.36
- 总市值 7.58亿
- 52周最高 3.455
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 1.54
- 委 比 28.36%
- 总股本 3.40亿
- 历史最高 15.23
- 量 比 0.90
- 振 幅 4.24%
- 历史最低 0.95
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvation Bio jumps after insiders purchase shares worth over $1.1M
Nuvation Bio (NYSE:NUVB) raced as much as 8% on Friday after SEC filings showed that insiders in the company bought shares worth $1.1M in the week. This was the highest total value of shares traded by...
06-20 23:19
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Nuvation Bio’s IBTROZI Receives FDA Approval
Nuvation Bio ( ($NUVB) ) has issued an announcement. On June 11, 2025, Nuvation...
06-12 04:51
Wedbush Maintains Outperform on Nuvation Bio, Maintains $5 Price Target
Wedbush analyst David Nierengarten maintains Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.
06-12 02:45
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral antitumor agent Ibtrozi as a treatment for certain patients with non-small cell l...
06-12 01:54
FDA Approves Taletrectinib For ROS1-Positive Non-Small Cell Lung Cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi,
06-12 00:50
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
JMP Securities Reiterates Market Outperform on Nuvation Bio, Maintains $6 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $6 price target.
06-02 23:28
